title: Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.
abstract: OBJECTIVE
  We analyzed the long-term oncologic outcome for patients with prostate cancer and transurethral resection who were treated using low-dose-rate (LDR) prostate brachytherapy.
  
  
  METHODS
  From January 2001 to December 2005, 57 consecutive patients were treated with clinically localized prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemical failure was defined according to the "Phoenix consensus". Patients were stratified as low and intermediate risk based on The Memorial Sloan Kettering group definition.
  
  
  RESULTS
  The median follow-up time for these 57 patients was 104 months. The overall survival according to Kaplan-Meier estimates was 88% (±6%) at 5 years and 77% (±6%) at 12 years. The 5 and 10 years for failure in tumour-free survival (TFS) was 96% and respectively (±2%), whereas for biochemical control was 94% and respectively (±3%) at 5 and 10 years, 98% (±1%) of patients being free of local recurrence. A patient reported incontinence after treatment (1.7%). The chronic genitourinary complains grade I were 7% and grade II, 10%. At six months 94% of patients reported no change in bowel function.
  
  
  CONCLUSIONS
  The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachytherapy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and clinical organ-confined prostate cancer.
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Pedro J
authors.initials: PJ
authors.lastname: Prada
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Anchuelo
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Ana Garcia
authors.initials: AG
authors.lastname: Blanco
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: Paya
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Cardenal
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Acuna
authors.affiliation: Department of Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Ferri
authors.affiliation: Department of Radiation Physics, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Andres
authors.initials: A
authors.lastname: Vazquez
authors.affiliation: Department of Radiation Physics, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Maite
authors.initials: M
authors.lastname: Pacheco
authors.affiliation: Department of Radiation Physics, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
authors.forename: Jesica
authors.initials: J
authors.lastname: Sanchez
mesh_terms: D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011879:Radiotherapy Dosage; D015203:Reproducibility of Results; D018570:Risk Assessment; D020728:Transurethral Resection of Prostate / Q000379:methods*; D014549:Urinary Incontinence / Q000209:etiology
chemical_list: D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen